
Opinion|Videos|January 7, 2025
Examining the AQUILA Trial Presented at ASH 2024
Panelists discuss how the AQUILA trial evaluated whether daratumumab monotherapy provides superior outcomes compared with active monitoring in high-risk smoldering multiple myeloma patients.




















